It has been nearly six months since the Pfizer deal and there is nothing on the horizon that indicates pSivida is likely to reach the first of these unqualified milestones. Pfizer has so far only provided funds in return for equity and now holds 10% of PSD stock. Why would they want to pay $200M for the licence of a single application of a pSivida technology when it can increase its holdings for a fraction of the cost (PSD market cap only $80M and a lot less without the Pfizer deal).
It doesn't matter how many 'investor' presentions pSivida makes nothing is going to change if the content is the tired old story we have heard for the last four or five months.
- Forums
- ASX - By Stock
- PSD
- cold corpse
PSD
psivida limited
cold corpse, page-3
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
HCH
Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered